Levetiracetam: A review of its adjunctive use in the management of partial onset seizures

Drugs

Volumn 60, Issue 4, 2000, Pages 871-893

  Dooley, M ^a   Plosker, G L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PLACEBO; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ASTHENIA; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TOLERANCE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HEADACHE; HUMAN; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; REVIEW; SOMNOLENCE; VERTIGO;

ANIMALIA;

EID: 0033756611     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060040-00004     Document Type: Review

References (60)

1. Commission on European Affairs: Appropriate standards of epilepsy care across Europe
2. New anti-epileptic drugs
3. Guidelines for epidemiologic studies on epilepsy
4. Diagnosis and treatment of partial seizures
5. Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation?
6. Levetiracetam (UCB LO59): Anticonvulsant effects are mediated by the parent compound
7. ucb L059, a novel anticonvulsant drug: Pharmacological profile in animals
8. The novel antiepilepticdrug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes
9. ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo
10. Effects of ucb L059, a potential anticonvulsant agent, on release of dopamine (DA) and its metabolites from cerebral ventricular perfusate induced by bicuculline (BIC) and haloperidol (HAL) in rats
11. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy
12. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats
13. Anticonvulsant effects of ucb L059 in rats: Absence of tolerance or discontinuation after chronic administration
14. Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission
15. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy
16. Cognitive performance is unaltered by levetiracetam (ucb L059) in the pilocarpine model of chronic epilepsy
17. Inhibition by levetiracetam of a non-GABA(A) receptor-associated epileptiform effect of bicuculline in rat hippocampus
18. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
19. Lack of negative impact on cognitive function differentiates levetiracetam (UCB L059) from other antiepileptic drugs
20. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain
21. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata
22. Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats
23. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs
24. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam
25. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy
26. Tiagabine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy
27. Levetiracetam: Towards a new class of antiepileptc drugs?
28. Levetiracetam
29. The pharmacokinetics of levetiracetam (ucb L059) in patients with intractable epilepsy
30. Evaluation of the pharmacokinetic and neuropsychometric parameters in chronic comedicated epileptic patients of three increasing dosages of a novel, antiepileptic drug, UCB L059 250-mg capsules per Os each dose for one week followed by two-weeks of placebo
31. Efficacy and tolerability study of ucb LO59 in patients with refractory epilepsy
32. No effect of liver impairment on the pharmacokinetics of levetiracetam
33. Single dose pharmacokinetics of levetiracetam in pediatric patients with partial epilepsy
34. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
35. Levetiracetam in a chronic limbic model of epilepsy
36. Microdialysis study of levetiracetam in rat frontal cortex and hippocampus
37. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractpry epilepsy
38. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
39. Multicenter doubleblind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures
40. Photosensitive epilepsy: A model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam
41. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique
42. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent
43. Influence of a new antiepileptic drug (levetiracetam, ucb L059) on the pharmacokinetics and pharmacodynamics of oral contraceptives
44. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial onset seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy
45. Efficacy and tolerability of 1,000-4,000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy
46. Efficacy and tolerability of levetiracetam (LEV) as add-on treatment in refractory epileptic patients with partial onset seizures: Analysis of the crossover part of the European trial
47. Levetiracetam in intractable partial epilepsy: Efficacy of add-on therapy and patient retention
48. Effectiveness of levetiracetam in reducing partial-onset seizures that are secondarily generalized (type IC)
49. Open-label efficacy and safety of levetiracetam in pediatric patients with partial onset seizures
50. Effect of levetiracetam on epilepsy-related quality of life
51. New antiepileptic drugs: A review of their current status and clinical potential
52. Epilepsy: (3) New treatments
53. Polypharmacy with anticonvulsants: Focus on synergism
54. Patients with refractory seizures
55. Plasma drug concentration monitoring of anticonvulsants: Practical guidelines
56. New antiepileptic drugs
57. Drug treatment of epilepsy